https://www.businesswire.com/news/home/20221031005048/en/Cognito-Therapeutics-to-Present-Clinical-Data-Evaluating-Gamma-Frequency-Neuromodulation-in-Alzheimer%E2%80%99s-Disease-at-2022-CTAD-Conference
0
0
10/31/22 at 12:00pm
Organization
Business Wire
Authors
Cognito Therapeutics, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today
Create an account
or login to join the discussion